Annovis Bio/$ANVS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Annovis Bio
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
Ticker
$ANVS
Sector
Primary listing
NYSE
Employees
7
Headquarters
Website
Annovis Bio Metrics
BasicAdvanced
$66M
-
-$1.40
1.31
-
Price and volume
Market cap
$66M
Beta
1.31
52-week high
$5.50
52-week low
$1.21
Average daily volume
961K
Financial strength
Current ratio
5.799
Quick ratio
5.373
Profitability
Management effectiveness
Return on assets (TTM)
-106.03%
Return on equity (TTM)
-220.61%
Valuation
Price to book
3.1
Price to tangible book (TTM)
3.1
Price to free cash flow (TTM)
-1.54
Free cash flow yield (TTM)
-64.93%
Free cash flow per share (TTM)
-1.247
Growth
Earnings per share change (TTM)
-39.12%
3-year earnings per share growth (CAGR)
-23.23%
What the Analysts think about Annovis Bio
Analyst ratings (Buy, Hold, Sell) for Annovis Bio stock.
Annovis Bio Financial Performance
Revenues and expenses
Annovis Bio Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Annovis Bio stock?
Annovis Bio (ANVS) has a market cap of $66M as of April 21, 2026.
What is the P/E ratio for Annovis Bio stock?
The price to earnings (P/E) ratio for Annovis Bio (ANVS) stock is 0 as of April 21, 2026.
Does Annovis Bio stock pay dividends?
No, Annovis Bio (ANVS) stock does not pay dividends to its shareholders as of April 21, 2026.
When is the next Annovis Bio dividend payment date?
Annovis Bio (ANVS) stock does not pay dividends to its shareholders.
What is the beta indicator for Annovis Bio?
Annovis Bio (ANVS) has a beta rating of 1.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.